Tumor Induced Osteomalacia Market By Product Type (Burosumab (Crysvita), Oral Phosphate Supplements, Active Vitamin D Analogs, Investigational FGFR Inhibitors); By Application (Unlocalized Tumors, Unresectable Tumors, Recurrent or Persistent TIO, Metastatic TIO); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research and Academic Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Tumor-Induced Osteomalacia Market: Surgical Cure Limits Long-Term Drug Demand While Targeted Therapy Builds a Recurring Revenue Pool

The Global Tumor-Induced Osteomalacia Market was valued at USD 118.6 million in 2025 and is projected to reach USD 170.4 million by 2032, expanding at a CAGR of 5.2% during the forecast period, according to Strategic Market Research.

 

Tumor-Induced Osteomalacia (TIO) is a rare paraneoplastic disorder in which FGF23-secreting tumors cause severe phosphate loss, weak bones, fractures, and muscle pain. Surgical removal of the tumor remains the only curative treatment, but patients with unresectable or unlocalized tumors require long-term therapy. Burosumab (Crysvita), the first FDA-approved targeted treatment for eligible adults and children aged two years and older, neutralizes excess FGF23 to restore phosphate reabsorption and active vitamin D production. Infigratinib, an investigational FGFR1–3 inhibitor, aims to suppress tumor growth and reduce FGF23 secretion at its source, while oral phosphate and calcitriol remain supportive options. Driven by improved diagnosis and growing access to targeted therapies.

 

Burosumab Turns Excess FGF23 Control into Recurring Pharmaceutical Revenue

Burosumab is a recombinant fully human monoclonal antibody that binds FGF23 and blocks its biological activity. Excess FGF23 reduces renal phosphate reabsorption and suppresses active vitamin D production. Neutralization allows the kidneys to return more phosphate to the bloodstream and supports active vitamin D production, linking the drug’s mechanism directly to the biochemical deficit that sustains TIO.

The commercial value comes from repeated administration. U.S. adult treatment starts every four weeks, while pediatric treatment starts every two weeks, equal to approximately 13 and 26 scheduled injections per patient-year before dose changes or interruptions. European treatment is also administered every two or four weeks, and trained patients or caregivers can self-administer after reaching a stable dose.

Burosumab, marketed as Crysvita, is jointly developed and commercialized by Kyowa Kirin globally and Ultragenyx Pharmaceutical in North America. The drug generated $481 million in U.S. and Canadian revenue in 2025, with 2026 sales reaching $93 million and full-year 2026 guidance of $500–$520 million. Globally, Crysvita has achieved blockbuster status, with sales exceeding ¥160 billion, or approximately $1.1 billion. The broader burosumab market, valued at about $400 million in 2025, is projected to reach $1.5 billion by 2035 at a 13.4% CAGR. Kyowa Kirin currently holds commercialization rights across approximately 40 countries in Europe, Asia-Pacific, and Latin America.

A 2026 Chinese post-marketing study treated nine adults every four weeks for up to 48 weeks, equivalent to about 12 scheduled treatment cycles during the observation period. Mean serum phosphorus increased from 1.2 mg/dL at baseline to 2.7 mg/dL at week 24 and 3.0 mg/dL at week 48. The study adds current local experience to a commercial pathway still controlled by diagnosis, reimbursement, specialist access, and continued inability to achieve curative surgery.

 

Infigratinib Proved Tumor-Directed FGFR Blockade but Did Not Produce Durable Remission

Infigratinib tested a different commercial strategy: reducing FGF23 production by targeting signaling within the tumor rather than neutralizing circulating FGF23. The oral molecule inhibits FGFR1–3. FN1–FGFR1 gene fusions have been identified as possible drivers in up to 40% of resected phosphaturic mesenchymal tumors, creating a molecular rationale for FGFR blockade.

The open-label Phase 2 study treated four adults—two with nonlocalized disease and two with nonresectable tumors—for up to 24 weeks. All four showed reductions in intact FGF23 and normalization of phosphate and active vitamin D while receiving treatment. The effect disappeared after discontinuation, biochemical values returned to baseline, and no patient entered durable biochemical remission.

Infigratinib targets previously treated patients with unresectable, locally advanced, or metastatic cholangiocarcinoma, representing an estimated initial addressable market of approximately $500 million. Commercialization in the United States has been jointly managed by BridgeBio Pharma and Helsinn Group. Despite the sizable theoretical market opportunity, the therapy has generated only single-digit millions of dollars in global sales, reflecting its niche patient population, limited commercial uptake, and competitive oncology treatment landscape.

 

Surgical Success Creates Pharmaceutical Attrition

Surgery and burosumab are complementary but commercially interactive. Burosumab controls phosphate loss while the causative tumor remains active; it does not remove the tumor. Localization can therefore continue after drug initiation.

FDA labeling directs clinicians to interrupt and reassess burosumab when the underlying tumor is treated. An adult receiving roughly 13 scheduled doses per year or a child receiving around 26 can leave the recurring drug pool after later localization and successful surgery. Two Japanese cases published in 2025 documented responsible tumors being discovered and resected during burosumab therapy, illustrating this movement from recurring treatment back to definitive intervention.

Incomplete resection produces the opposite revenue effect. The 34.1% refractory share in the 44-patient specialist cohort supports additional imaging, repeat surgery, conventional therapy, and extended burosumab use. Pharmaceutical value is highest among patients who remain clinically active, reimbursed, and outside a curative surgical pathway.

 

European Epidemiology Confirms an Ultra-Rare Addressable Base

Germany’s claims-based study estimated 2019 prevalence at 0.187 per 100,000 people and incidence at no more than 0.094 per 100,000 person-years. The annual new-patient rate was roughly half the prevalence rate, indicating a small flow of newly identifiable patients relative to the existing pool.

Denmark reported upper-bound prevalence of 0.70 per 100,000 in the total population and 0.43 per 100,000 among adults. Incidence remained below 0.13 per 100,000 person-years overall and 0.10 among adult-onset cases.

These country estimates confirm that commercial expansion depends on specialist referral efficiency rather than broad population reach. Diagnosed prevalence also remains larger than the treated pool because patients divide among surgical candidates, conventional-therapy users, burosumab-eligible patients, and those still undergoing localization.

 

Home Administration Shifts Value Toward Supply and Patient Support

The EMA permits patient or caregiver administration after the dose has stabilized and training has been completed. Japan has supported self-injection for the wider FGF23-related hypophosphatemic rickets and osteomalacia indication since December 2020. Kyowa Kirin launched a ready-to-use prefilled syringe in November 2025 after receiving Japanese approval in June.

Home administration reduces repeated facility attendance for patients receiving 13 or 26 scheduled injections annually. Revenue moves toward product supply, specialty distribution, adherence support, and home-treatment services. The prefilled presentation also removes manual preparation and is designed to reduce the treatment burden for patients, families, and healthcare professionals.

 

Crysvita Revenue Concentration Supports a Specialist Commercial Model

Kyowa Kirin reported global Crysvita revenue of ¥216.4 billion in 2025, up 10% from ¥196.6 billion in 2024. North America generated ¥141.8 billion, representing 65.5% of franchise revenue. EMEA contributed ¥57.5 billion, or 26.6%; Japan supplied ¥13.6 billion, or 6.3%; and other markets generated ¥3.5 billion, or 1.6%. North America and EMEA together accounted for 92.1%.

These shares describe the broader Crysvita franchise, which is led by X-linked hypophosphatemia, but they also show where manufacturing, reimbursement, specialist sales, and patient-support infrastructure is strongest. TIO enters an established rare-disease commercial system rather than requiring a standalone launch network.

Burosumab’s U.S. orphan approval for TIO dates to June 2020, with exclusivity listed through June 18, 2027. Infigratinib has not moved into an approved competing position, leaving competition centered on conventional phosphate and active vitamin D, payer controls, curative surgery, and potential future targeted entrants.

 

Specialist Networks Will Determine Regional Conversion

The United States combines FDA approval, dose-linked medical-benefit billing, and detailed commercial-payer criteria. North America’s 65.5% share of Kyowa Kirin’s wider 2025 Crysvita revenue indicates the scale of the regional franchise, while TIO growth depends on case identification, payer conversion, and treatment retention.

Europe has a common authorization for eligible patients from one year of age, but reimbursement and delivery remain country specific. EMEA represented 26.6% of Kyowa Kirin’s Crysvita revenue, making it the second-largest wider-franchise region. Germany and Denmark provide epidemiological boundaries, while national systems decide how many diagnosed patients reach treatment.

Japan combines documented surgical practice with self-injection access and a prefilled formulation. China added nine-patient Phase 4 evidence in 2026. Across regions, metabolic-bone centers, SSTR-PET/CT availability, experienced surgeons, and rare-disease reimbursement channels matter more than population totals alone.

 

Case Finding and Treatment Sequencing Will Shape Growth Through 2032

The Tumor-Induced Osteomalacia Market will grow as phosphate testing, specialist referral, functional imaging, burosumab access, and home administration convert more hidden patients into treated cases. Growth will remain moderated by the ultra-rare patient base, payer step requirements, annual reauthorization, and surgical cures that remove patients from recurring drug use.

Localized and completely resectable TIO will remain the dominant clinical pathway, supported by 97.6% clinical improvement following resection. Unlocalized, unresectable, persistent, and recurrent disease will produce the strongest recurring pharmaceutical value. Infigratinib’s four-patient study adds molecular proof of concept, but its lack of post-treatment remission keeps the current commercial market centered on surgery and sustained FGF23 neutralization.

Commercial performance through 2032 will depend on how quickly healthcare systems identify patients, how often imaging finds the responsible tumor, whether surgeons achieve complete margins, and how long eligible patients remain on reimbursed treatment. These variables determine how the market’s projected 43.7% cumulative growth is divided between hospital services and pharmaceutical revenue.

 

Tumor-Induced Osteomalacia Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 118.6 Million
Revenue Forecast in 2032	USD 170.4 Million
Overall Growth Rate	CAGR of 5.2% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Region
By Product Type	Burosumab (Crysvita), Oral Phosphate Supplements, Active Vitamin D Analogs, Investigational FGFR Inhibitors
By Application	Unlocalized Tumors, Unresectable Tumors, Recurrent or Persistent TIO, Metastatic TIO
By End User	Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Research and Academic Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising awareness and diagnosis of rare phosphate-wasting disorders; Increasing adoption of targeted therapies for tumor-induced osteomalacia; Growing investments in rare disease research and specialty care infrastructure
Customization Option	Available upon request